Searching map area
Cetuximab
? TBD
Pharmaceutical drug
Join to rate
Ratings 0
Nobody has rated this yet. Be the first!
Subject of 6
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
scientific article
Systemic chemotherapy plus cetuximab after complete surgery in the treatment of isolated colorectal peritoneal carcinoma: COCHISE phase II clinical trial
scientific article published on 22 July 2019
Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.
scientific article
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
scientific article
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205
scientific article
Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
scientific article
Lists 0
Join to rate
Wikipedia

Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion.

Instance of
type of chemical entity
Subclass of
Chemical compound
References
Wikidata